The endocannabinoid system: Critical for the neurotrophic action of psychotropic drugs

Biomedical Reviews

Volumn 21, Issue , 2010, Pages 31-46

  Hassanzadeh, Parichehr ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brain; Endocannabinoids; NGF; Psychotropics

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; LEPTIN; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PSYCHOTROPIC AGENT; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST;

ANALGESIA; ANTINOCICEPTION; APPETITE; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NERVE FUNCTION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TARGETING; PSYCHOPATHY; REPERFUSION INJURY; REPRODUCTION; REVIEW; REWARD; SIGNAL TRANSDUCTION;

EID: 80053418573     PISSN: 1310392X     EISSN: None     Source Type: Journal    
DOI: 10.14748/bmr.v21.45     Document Type: Review

References (179)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder. JAMA 2003; 289(23): 3095-3105.
2. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12: 2-19.
3. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
4. McEwen BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005; 54: 20-23.
5. Lu XY. The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol 2007; 7: 648-652.
6. Gertler A. Role of leptin in early metabolic programming. Adipobiology 2009; 1: 27-34.
7. Bun-Hee L, Aye-Mu M, Yong-Ku K. Psychotropic drugs on in vitro brain-derived neurotrophic factor production in whole blood cell cultures from healthy subjects. J Clin Psychopharm 2010; 30: 623-627.
8. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-593.
9. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545-1564.
10. Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci 2006; 110: 175-191.
11. Greene LA, Kaplan DR. Early events in neurotrophin signaling via Trk and p75 receptors. Curr Opin Neurobiol 1995; 5: 579-587.
12. Gallo G, Letourneau PC. Localized sources of neurotrophins initiate axon collateral sprouting. J Neurosci 1998; 18: 5403-5414.
13. McAllister AK, Lo DC, Katz LC. Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 1995; 15: 791-803.
14. Song HJ, Ming GL, Poo MM. A cAMP-induced witching of turning direction of nerve growth cones. Nature 1997; 388: 275-279.
15. Lesser SS, Sherwood NT, Lo DC. Neurotrophins differentially regulate voltage-gated ion channels. Mol Cell Neurosci 1997; 10: 173-183.
16. Lohof AM, Ip NY, Poo MM. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature 1993; 363: 350-353.
17. Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 1995; 267: 1658-1662.
18. Hans T. Neurotrophins and neuronal plasticity. Science 1995; 270: 593-598.
19. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24-32.
20. Schulte-Herbrüggen O, Jockers-Scherübl MC, Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 38-44.
21. Shaltiel G, Chen G, Manji HK. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007; 7: 22-26.
22. Pacher P, Kohegyi E, Kecskemeti V, Furs S. Current trends in the development of new antidepressants. Curr Med Chem 2001; 8: 89-100.
23. Vaida VA, Duman RS. Depression: emerging insights from neurobiology. Br Med Bull 2001; 57: 61-79.
24. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16: 239-249.
25. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45: 553-563.
26. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and Trkb mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatment. J Neurosci 1995; 15: 7539-7547.
27. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J Neurosci 2002; 22: 3251-3261.
28. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45: 104-114.
29. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143-148.
30. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.
31. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-75.
32. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-137.
33. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703-709.
34. Van Hoomissen JD, Chambliss HO, Holmes PV, Dishman RK. Effects of chronic exercise and imipramine on mRNA for BDNF after olfactory bulbectomy in rat. Brain Res 2003; 974: 228-235.
35. Alvin V, Terry J, Debra A, Warner GS, Hohnadel EJ, Middlemore ML, et al. Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats. Neuroscience 2007; 150: 413-424.
36. Angelucci F, Aloe L, Gruber SHM, Fiore M, Mathé AA. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int J Neuropsychopharm 2000; 3: 13-25.
37. Vinay P, KhanMohammad M, Alvin T, Sahebarao PM. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J Psychiat Res 2004; 38: 521-529.
38. Levi-Montalcini R. The nerve growth factors 35 years later. Science 1987; 237: 1154-1162.
39. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19: 514-520.
40. Levi-Montalcini R. The nerve growth factor and the neuroscience chess board. Prog Brain Res 2004; 146: 525-527.
41. Ebendal T. Function and evolution in the NGF family and its receptors. J Neurosci Res 1992; 32: 461-470.
42. Lad SP, Neet KE, Mufson EJ. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2003; 2: 315-334.
43. Arredondo LR, Deng C, Ratts RB, Lovett-Racke AE, Holtzman DM, Racke MK. Role of nerve growth factor in experimental autoimmune encephalomyelitis. Eur J Immunol 2001; 31: 625-633.
44. Aloe L, Tirassa P, Bracci-Laudiero L. Nerve growth factor in neurological and non neurological diseases: Basic findngs and emerging pharmacological prospective. Curr Pharmacol Design 2001; 7: 113-123.
45. Tuveri M, Generine S, Matucci-Cenerini M, Aloe L. Nerve growth factor, a useful tool in the treatment of chronic vasculitis ulcers in rheumatoid arthritis. Lancet 2000; 356: 1739-1740.
46. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signalling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 2009; 20: 133-145.
47. Sun W, Sun C, Lin H, Zhao H, Wang J, Ma H, et al. The effect of collagen-binding NGF-beta on the promotion of sciatic nerve regeneration in a rat sciatic nerve crush injury model. Biomaterials 2009; 30: 4649-4656.
48. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004; 146: 279-289.
49. Chaldakov GN, Fiore M, Tonchev AB, Dimitrov D, Pancheva R, Rancic G, et al. Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight. Curr Pharm Des 2007; 13: 2176-2179.
50. Lapchak PA, Araujo DM. NGF suppression of weight gain in adult female rats correlates with decreased hypothalamic cholecystokinin levels. Brain Res 1994; 655: 12-16.
51. Kawamoto K, Matsuda H. Nerve growth factor and wound healing. Prog Brain Res 2004; 146: 369-84.
52. Tuveri MA, Triaca V, Aloe L. The nerve growth factor induces cutaneous ulcer healing in "non-responder" tranplanted skin. Ann Ist Super Sanita 2006; 42: 94-96.
53. Lambiase A, Manni L, Rama P, Bonini S. Clinical application of nerve growth factor on human corneal ulcer. Arch Ital Biol 2003; 141: 141-148.
54. Sornelli F, Fiore M, Chaldakov GN, Aloe L. Adipose tissue-derived nerve growth factor and brain-derived neurotrophic factor: results from experimental stress and diabetes. Gen Physiol Biophys 2009; 28: 179-183.
55. Chaldakov GN, Tonchev AB, Aloe L. NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. Relevance to neuropsychiatric and cardiometabolic diseases. Riv Psichiatr 2009; 44: 79-87.
56. Heitz C, Descombes JJ, Miller RC, Stoclet JC. α-adrenoceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol 1986; 123: 279-285.
57. 2+ channels in rat hipppocampal CA1 pyramidal neurons. Br J Pharmacol 1990; 100: 705-710.
58. Nishio T, Sunohara N, Furukawa S, Akiguchi I, Kudo Y. Repeated injections of nicergoline increase the nerve growth factor level in the aged rat brain. Jpn J Pharmacol 1998; 76: 321-323.
59. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006; 27: 85-91.
60. Otten U, Baumann JB, Girard J. Stimulation of the pituitary-adrenocortical axis by nerve growth factor. Nature 1979; 282: 413-414.
61. Enzo E, Pierluigi P, Marika B, Piercarlo M, Marco B, Diego G. Raised plasma nerve growth factor levels associated with early-stage romantic love. Psychoneuroendocrinology 2006; 31(3): 288-294.
62. Lim MM, Young LJ. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm Behav 2006; 50: 506-517.
63. Kendrick KM. The neurobiology of social bonds. J Neuroendocrinol 2004; 16: 1007-1008.
64. Angelucci F, Aloe L, Vasquez PJ, Mathe AA. Mapping the differences in the brain concentration of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in an animal model of depression. Neuroreport 2000; 11(6): 1369-1373.
65. Chaldakov GN, Tonchev A, Aloe L. NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. Relevance to neuropsychiatric and cardiometabolic. Riv Psichiatr 2009; 44: 79-87.
66. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 2003; 60: 117-123.
67. Alleva E, Petruzzi S, Cirulli F, Aloe L. NGF regulatory role in stress and coping of rodents and humans. Pharmacol Biochem Behav 1996; 54: 65-72.
68. Hassanzadeh P, Hassanzadeh A. Effects of different psychotropic agents on the central nerve growth factor protein. Iran J Basic Med Sci 2010; 13: 202-209.
69. Hassanzadeh P, Rahimpour S. The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology 2010; (doi 10.1007/s00213-010-2120-4, Epub ahead of print).
70. Hellweg R, Lang UE, Nagel M, Baumgartner A. Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 2002; 7: 604-608.
71. Valvassori SS, Stertz L, Andrezza AC, Rosa MI, Kapczinski F, Streck EL, et al. Lack of effect of antipsychotics on BDNF and NGF levels in the hippocampus of rat. Metab Brain Dis 2008; 23: 213-219.
72. Pillai A, Terry Jr. AV, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006; 82: 95-106.
73. Dableh LJ, Yashpal K, Rochford J, Henry JL. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 2005; 507: 99-105.
74. Griebel G, Perrault G, Soubrié P. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology 2001; 158: 241-251.
75. Salomé N, Stemmelin J, Cohen C, Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic-and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 2006; 83: 533-539.
76. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, et al. The gerbil elevated plus-maze II: anxiolytic effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 2002; 27: 372-379.
77. Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 2003; 14: 87-95.
78. Zocchi A, Varnier G, Arban R, Griffante C, Zanetti L, Bettelini L, et al. Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci Lett 2003; 345: 73-76.
79. Bensaid M, Faucheux BA, Hirsch E, Agid Y, Soubrie P, Oury-Donat F. Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 2001; 303: 25-28.
80. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74: 1445-1463.
81. Duric V, McCarson KE. Neurokinin-1 (NK-1) receptor and brain-derived neurotrophic factor (BDNF) gene expression is differentially modulated in the rat spinal dorsal horn and hippocampus during inflammatory pain. Mol Pain 2007; 3: 32.
82. Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, Sheasby A, et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003; 18: 1828-1836.
83. Hassanzadeh P, Hassanzadeh A. Involvement of the cannabinoid and neurotrophin systems in the mechanisms of action of neurokinin receptor antagonists. Eur Neuropsychopharmacol 2011 (in press).
84. Banasr M, Valentine GW, Li XY, Gourley SL, Taylor JR, Duman RS. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiat 2007; 62: 496-504.
85. Duman R. Depression: A case of neuronal life and death? Biol Psychiatry 2004; 56: 140-145.
86. Conner JM, Franks KM, Titterness AK, Russell K, Merrill DA, Christie BR, et al. NGF is essential for hippocampal plasticity and learning. J Neurosci 2009; 29: 10883-10889.
87. Winkler J, Ramirez GA, Thal LJ, Waite JJ. Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors. J Neurosci 2000; 20(2): 834-844.
88. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink, R. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 2009; 29: 1388-1398.
89. Vink R, Nimmo AJ, Cernak I. An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin Exp Pharmacol Physiol 2001; 28: 919-921.
90. Miwa T, Moriizumi T, Horikawa I, Uramoto N, Ishimaru T, Nishimura T, et al. Role of nerve growth factor in the olfactory system. Microsc Res Tech 2002; 58: 197-203.
91. Moises HC, Womble MD, Washburn MS, Williams LR. Nerve growth factor facilitates cholinergic neurotransmission between nucleus basalis and the amygdala in rat: an electrophysiological analysis. J Neurosci 1995; 15: 8131-8142.
92. Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Design 2009; 15: 1623-1646.
93. Aso E, Ozaita A, Valdizán EM, Ledent C, Pazos A, Maldonado R. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008; 105: 565-572.
94. Williams EJ, Walsh FS, Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol 2003; 160: 481-486.
95. Lemtiri-Chlieh F, Levine ES. BDNF evokes release of endogenous cannabinoids at layer 2/3 inhibitory synapses in the neocortex. J Neurophysiol 2010; 285: 19002-19011.
96. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuroremodulatory action. Trends Neurosci 1998; 21: 521-528.
97. Fernández-Ruiz JJ, Berrendero F, Hernández ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000; 23: 14-20.
98. Hungund BL, Basavarajappa BS. Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence. Alcohol Alcohol 2000; 35: 126-133.
99. Yamamoto T, Takada K. Role of cannabinoid receptors in the brain as it relates to drug reward. Jpn J Pharmacol 2000; 84: 229-236.
100. Di Marzo V. Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998; 1392: 153-175.
101. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signalling in the hippocampus. Neuron 2001; 31: 453-462.
102. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-592.
103. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36: 3032-3034.
104. 1 receptor-mediated inhibition of hippocampal acetylcholine release is preserved in aged mice. Br J Pharmacol 2003; 138: 1425-1430.
105. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180.
106. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000; 97: 5044-5049.
107. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43-50.
108. Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 1991; 47: 257-261.
109. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-583.
110. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
111. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
112. Calignano A, La Rana G, Loubet-Lescoulie P, Piomelli D. A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog Brain Res 2000; 129, 471-482.
113. GÜhring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C. A role for endocannabinoids in indomethacin induced spinal antinociception. Eu J Pharmacol 2002; 454: 153-163.
114. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848: 183-190.
115. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol 2001; 117: 116-124.
116. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos A, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-294.
117. Cichewicz DL, Martin Z, Smith FL, Welch, SP. Enhancement of opioid potency with inactive oral administration of D9-THC: Dose response analysis and receptor characterization. J Pharmacol Exp Ther 1999; 289: 859-867.
118. Pugh GJ, Smith P, Dombrowski D, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of D9-THC and morphine in the spinal cord. J Pharmacol Exp Ther 1996; 279: 608-616.
119. Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with D9-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 2001; 297: 121-127.
120. Rowen DW, Embrey JP, Moore CH, Welch SP. Antisense oligodeoxynucleotides to Kappa1 receptor enhance D9-THC-induced antinociceptive tolerance. Pharmacol Biochem Behav 1998; 59: 399-404.
121. Sala M, Braida D, Leone MP, Calcaterra P, Frattola D, Gori E. Chronic morphine affects working memory during treatment and withdrawal in rats: possible residual long-term impairment. Behav Pharmacol 1994; 5: 570-580.
122. Vigano D, Cascio MG, Rubino T, Fezza F, Vaccani A, Di Marzo V, et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 2003: 28: 1160-1167.
123. Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, et al. Identification of the endocannabinoids and related compounds in human fatty cells. Obesity 2007; 15: 837-845.
124. Fride E. The endocannabinoid-CB receptor system: A new player in the brain-gut-adipose field. Biomed Rev 2006; 17: 23-42.
125. Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 2006; 5: 272-292.
126. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
127. Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, et al. Trick or treat from food endocannabinoids? Nature 1998; 396: 636-637.
128. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
129. Yoshida R, Ohkuri T, Jyotaki M, Yasuo T, Horio N, Yasumatsu K, et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 2010; 107: 935-939.
130. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self administration. J Neurosci 2001; 21: 5344-5350.
131. Hungund BL, Basavarajappa BS, Vadasz C, Kunos G, Rodriguez de Fonseca F, Colombo G, et al. Ethanol, endocannabinoids, and the cannabinoidergic signaling system. Alcohol Clin Exp Res 2002; 26: 565-574.
132. Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidyl-ethanolamine in SK-N-SH cells. J Neurochem 1999; 72: 522-528.
133. González S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002; 954: 73-81.
134. Beheshtian A, Salmasi AH, Payabvash S, Kiumehr S, Nezami BG, Rahimpour S, et al. Role of endogenous cannabinoids in ischemia/reperfusion injury following testicular torsion in rats. Int J Urol 2008; 15: 449-454.
135. Pacher P, Haskó G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2008; 153: 252-262.
136. Wang H, Xie H, Dey SK. Endocannabinoid signaling directs periimplantation events. AAPS J 2006; 8: E425-E432.
137. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA 1995; 92 (10): 4332-4336.
138. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000; 355: 1326-1329.
139. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975; 55: 597-602.
140. Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M. et al. Δ9-Tetrahydrocannabinol-induced apoptosis in jurkat leukemia T cells is regulated by translocation of bad to mitochondria. Mol Cancer Res 2006; 4: 549-562
141. Pushkarev VM, Kovzun OI. Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers? Exp Oncol 2008; 30: 6-21.
142. Pang Z, Geddes JW. Mechanisms of cell death induced by the mitochondrial toxin 3 nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J Neurosci 1997; 17: 3064-3073.
143. Jackson SJ, Diemel LT, Pryce G, Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurosci 2005; 25: 1904-1913.
144. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-531.
145. Ramirez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-1913.
146. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, et al. WIN55212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model Parkinson's disease. Eur J Neurosci 2009; 29: 2177-2186.
147. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005; 19: 96-107.
148. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Faseb J 2000; 14: 1432-1438.
149. Centonze D, Rossi S, Finazzi-Agrò A, Bernardi G, Maccarrone M. The Endocannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int Rev Neurobiol 2007; 82: 171-186.
150. Huntley A. A review of the evidence for efficacy of complementary and alternative medicines in MS. Int MS J 2006; 13: 5-12.
151. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
152. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23: 2511-2516.
153. 1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res 2006; 1107: 199-205.
154. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002; 22: 9742-9753.
155. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, et al. Cultured rat microglial cells synthesize the endocannabinoid 2-Arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 2004; 65: 999-1007.
156. Fowler CJ. Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. Curr Drug Targets CNS Neurol Disord 2005; 4: 685-696.
157. Shen M, Thaye, SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998; 54: 459-462.
158. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 2001; 13: 1529-1536.
159. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-2995.
160. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 2000; 278: 157-160.
161. Van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, Nicolay K, Veldink GA, et al. Acute neuronal injury, excitotoxicity and the endocannabinoid system. Mol Neurobiol 2002; 26: 317-346.
162. Diana MA, Bregestovski P. Calcium and endocannabinoids in the modulation of inhibitory synaptic transmission. Cell Calcium 2005; 37: 497-505.
163. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002; 80: 448-456.
164. 1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR141716 (Rimonabant) in rodents. Br J Pharmacol 2003; 140(1): 115-122.
165. Van der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 2005; 7: 37-50.
166. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich, A. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003: 302: 84-88.
167. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004; 19: 1691-1698.
168. Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004; 75: 2959-2970.
169. Hassanzadeh P, Hassanzadeh A. The role of the endocannabinoids in suppression of the HPA axis activity by doxepin. Iran J Basic Med Sci 2011 (in press).
170. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-18625.
171. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547.
172. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 2005; 16: 333-352.
173. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 2009; 30: 484-493.
174. Haller J, Varga B, Ledent C, Barna I, Freund TF. Context dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004; 19: 1906-1912.
175. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107-115.
176. Navarro M, Hernandez E, Munoz RM, del Acro I, Villanua MA, Carrera MRA. Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491-496.
177. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006; 318: 304-310.
178. Jenny M, Schröcksnadel S, Überall F, Fuchs D. The potential role of cannabinoids in modulating serotonergic signaling by their influence on tryptophan metabolism. Pharmaceuticals 2010; 3: 2647-2660.
179. Galve-Roperh I, Aguado T, alazuelos J, Guzmán M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007; 13: 109-114.